Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aquapharm Biodiscovery, a marine biotechnology company, has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its collection of marine micro-organisms.
Subscribe to our email newsletter
AMRI is expected to screen Aquapharm’s library against Gram-negative and Gram-positive bacteria and an undisclosed anti-inflammatory target. Additionally it is also expected to isolate and elucidate the structures of novel hits. Aquapharm retains all rights to compounds resulting from the collaboration.
Aquapharm and AMRI are expected to provide the initial results during 2011.
Simon Best, CEO of Aquapharm, said: “We are confident that this collaboration will exploit the novelty, diversity and drug-like characteristics of the compounds which we know from pilot studies are abundantly produced by marine micro-organisms.
“These represent a virtually untapped source of compounds and scaffolds with many attractive characteristics to form the basis of numerous drug-discovery partnerships.”